These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 10642222)

  • 41. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sustained release oral fampridine in the treatment of multiple sclerosis.
    Kachuck NJ
    Expert Opin Pharmacother; 2009 Aug; 10(12):2025-35. PubMed ID: 19586420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
    Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J
    Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Symptomatic therapy in multiple sclerosis: Big pharma should do more--commentary.
    Hutchinson M
    Mult Scler; 2015 Jul; 21(8):982-3. PubMed ID: 26084346
    [No Abstract]   [Full Text] [Related]  

  • 46. Doug williams.
    Williams D; Mullard A
    Nat Rev Drug Discov; 2014 Dec; 13(12):880-1. PubMed ID: 25435210
    [No Abstract]   [Full Text] [Related]  

  • 47. Developments in MS over the Past 17 Years the MS Forum and The International MS Journal.
    Bates PD; Jacobson S
    Int MS J; 2011 Sep; 17(3):75. PubMed ID: 21689488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patient organizations' funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey.
    Colombo C; Mosconi P; Villani W; Garattini S
    PLoS One; 2012; 7(5):e34974. PubMed ID: 22590498
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient empowerment as a component of health system reforms: rights, benefits and vested interests.
    Colombo C; Moja L; Gonzalez-Lorenzo M; Liberati A; Mosconi P
    Intern Emerg Med; 2012 Apr; 7(2):183-7. PubMed ID: 22278387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug companies offer DM programs for MS patients.
    Dis Manag Advis; 2002 Nov; 8(11):165-8, 161. PubMed ID: 12506456
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biogen, Serono squabble over MS market.
    Davidson S
    Nat Biotechnol; 2001 Aug; 19(8):696-7. PubMed ID: 11479543
    [No Abstract]   [Full Text] [Related]  

  • 52. Infections cast cloud over Novartis' MS therapy.
    Garber K
    Nat Biotechnol; 2008 Aug; 26(8):844-5. PubMed ID: 18688218
    [No Abstract]   [Full Text] [Related]  

  • 53. [Promising results with methylprednisolone in multiple sclerosis. Lack of patent rights makes drug industry less interested].
    Kling A; Dahlqvist R
    Lakartidningen; 2007 Jan 17-23; 104(3):128-30. PubMed ID: 17302117
    [No Abstract]   [Full Text] [Related]  

  • 54. Drug companies seek MS patients to lobby for new products.
    Yamey G
    BMJ; 2000 Jan; 320(7229):207. PubMed ID: 10642222
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.